Abonnement à la biblothèque: Guest
Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections
Forum on Immunopathological Diseases and Therapeutics
SJR: 0.309 SNIP: 0.041 CiteScore™: 0.18

ISSN Imprimer: 2151-8017
ISSN En ligne: 2151-8025

Archives: Volume 1, 2010 to Volume 7, 2016

Forum on Immunopathological Diseases and Therapeutics

DOI: 10.1615/ForumImmunDisTher.2015014118
pages 195-214

Druggable Targets in Pancreatic Adenocarcinoma

Stefania Nobili
Department of Health Sciences, University of Florence, Firenze, Italy
Renato Tassi
Department of Experimental and Clinical Medicine, University of Florence, Firenze, Italy
Ida Landini
Department of Experimental and Clinical Medicine, University of Florence, Firenze, Italy
Gabriele Perrone
Department of Health Sciences, University of Florence, Firenze, Italy
Cristina Napoli
Department of Health Sciences, University of Florence, Firenze, Italy
Enrico Mini
Department of Experimental and Clinical Medicine, University of Florence, Firenze, Italy

RÉSUMÉ

Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related death worldwide. It is often diagnosed at an advanced or metastatic stage and results of the approved systemic therapies are discouraging, making PDAC one of most lethal cancers in Western countries. In recent years, a better comprehension of PDAC unique biology has disclosed new potential targets for therapeutic interventions. Meanwhile, the development of conjugated agents, small molecules, antibodies, and immunoagents has opened therapeutic opportunities for drugs able to exert therapeutic effects on druggable targets of PDAC biology. Despite some failures, this approach is bringing meaningful results from bench to bedside, and more efficacious therapeutic opportunities may become available for PDAC treatment. In this review, we discuss the main hallmarks of PDAC biology as its microenvironment, cancer-driving proliferative pathways, growth suppression loops, and how PDAC evades immune system surveillance, as well as molecular aspects of each feature. The main preclinical and clinical results of each targeted intervention are also presented considering its biological rationale. Ongoing clinical trials provide evidence of the effectiveness of this approach and promising results in the treatment of PDAC.


Articles with similar content:

Cancer and Cancer Stem Cells: New Molecular Perspectives
Critical Reviews™ in Oncogenesis, Vol.24, 2019, issue 1
Onur Sahin, Gokce Ceren Kuscu, Gulperi Oktem, Elif Tunc, Funda Cagirir Dindaroglu, Cevik Gurel, Ismet Hortu, Gizem Inetas, Aylin Buhur
Prospects for the Development and Use of Gram-Negative Bacterial Virulence Protein Secretion Inhibitors for Prophylaxis and Treatment of Infectious Diseases
Critical Reviews™ in Immunology, Vol.30, 2010, issue 1
Heather B. Felise, Samuel I. Miller
IL-7 and Its Beneficial Role in Sepsis-Induced T Lymphocyte Dysfunction
Critical Reviews™ in Immunology, Vol.38, 2018, issue 6
Fabienne Venet, Charles de Roquetaillade, Guillaume Monneret, Morgane Gossez
Venoms Can Be a Boon for Cancer Patients
Forum on Immunopathological Diseases and Therapeutics, Vol.4, 2013, issue 3-4
Sudhir Kumar, Ruchi Jain, Puja Sarkar
Noncoding RNAs (ncRNA) in Hepato Cancer: A Review
Journal of Environmental Pathology, Toxicology and Oncology, Vol.37, 2018, issue 1
Xiujuan Sun, Anshoo Malhotra